Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 12Recruiting 4Active not recruiting 3Unknown 2Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Recurrence 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Renal Insufficiency 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2beta-Thalassemia 1Waldenstrom Macroglobulinemia 1Thalassemia 1Plasmablastic Lymphoma 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Anemia, Sickle Cell 1Amyloidosis 1Acute-Phase Reaction 1

Interventions

daratumumab 6Dexamethasone 6pomalidomide 4Bortezomib 4Focal Adhesion Protein-Tyrosine Kinases 3venetoclax 2Specimen Handling 2Cyclophosphamide 2Calcium Dobesilate 2talquetamab 1ixazomib 1idecabtagene vicleucel 1dexamethasone acetate 1dexamethasone 21-phosphate 1darlin protein, Dictyostelium 1belantamab mafodotin 1auricularum 1X-Rays 1Tissue Banks 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Pharmaceutical Preparations 1Phantoms, Imaging 1Melphalan 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Biopsy 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Immunoglobulin Light-chain Amyloidosis × Bortezomib × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Peking University People's Hospital

Phase NA Recruiting
41 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Peking University People's Hospital

Recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06342466 2024-12-30

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

Peking University People's Hospital

Phase 2 Recruiting
40 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡